Author

A. Malovannaya

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Organism:human· 3 Assay:proteomics· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2

Frequent Co-Authors

A. B. Saltzman· 3 shared M. J. Ellis· 3 shared B. Zhang· 2 shared B.-J. Kim· 2 shared C. Perou· 2 shared D. Chan· 2 shared E. J. Jaehnig· 2 shared J. Wang· 2 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. B. Saltzman

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor

W. C. Fiskus, J. Piel, M. Collins, M. Hentemann, B. Cuglievan, C. P. Mill, C. E. Birdwell, K. Das, J. A. Davis, H. Hou, A. C. Jain, A. Malovannaya, T. M. Kadia, N. Daver, K. Sasaki, , K. N. Bhalla

This study shows that FHD-286, a BRG1/BRM inhibitor, reduces AML burden and improves survival when combined with Menin or BET inhibitors in xenograft models of AML with MLL1r or mtNPM1.

bioRxiv · Sep 28, 2023Cancer Biology

Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer

N. Zhao, E. Kabotyanski, A. Saltzman, A. Malovannaya, X. Yuan, L. Reineke, N. Lieu, Y. Gao, D. Pedroza, S. Calderon, A. Smith, C. Hamor, K. Safari, S. Savage, B. Zhang, , J. Rosen

Zotatifin targets EIF4A to suppress TNBC by inhibiting Sox4, inducing interferon response, and reprogramming the tumor immune microenvironment, synergizing with chemotherapy.

bioRxiv · Sep 28, 2023Cancer Biology

Kinase Inhibitor Pulldown Assay (KiP) for Clinical Proteomics

A. B. Saltzman, D. Chan, M. V. Holt, J. Wang, E. J. Jaehnig, M. Anurag, P. Singh, A. Malovannaya, B.-J. Kim, M. J. Ellis

The paper introduces a kinase inhibitor pulldown assay (KiP) combined with PRM for clinical proteomics, improving kinase quantification in cancer samples.

bioRxiv · Oct 13, 2022Biochemistry

A Network Approach to Identify Biomarkers of Differential Chemotherapy Response Using Patient-Derived Xenografts of Triple-Negative Breast Cancer

V. Petrosyan, L. E. Dobrolecki, L. Thistlethwaite, A. N. Lewis, C. Sallas, R. Rajaram, J. T. Lei, M. J. Ellis, K. Osborne, M. Rimawi, A. Pavlick, M. Shafaee, H. Dowst, A. B. Saltzman, A. Malovannaya, , M. T. Lewis

This paper identifies biomarkers of differential chemotherapy response in TNBC using a network-based approach and validates them in PDX models and clinical datasets.

bioRxiv · Aug 20, 2021 · PreprintCancer Biology

Microscaled Proteogenomic Methods for Precision Oncology

S. Satpathy, E. J. Jaehnig, K. Krug, B.-J. Kim, A. B. Saltzman, D. Chan, K. R. Holloway, M. Anurag, C. Huang, P. Singh, A. Gao, N. Namai, Y. Dou, B. Wen, S. Vasaikar, , M. J. Ellis

This study develops microscaled proteogenomic methods for cancer analysis, showing treatment response and resistance mechanisms in ERBB2-positive breast cancers.

bioRxiv · Oct 9, 2019Cancer Biology